These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32351833)

  • 21. Quantification of myocardial interstitial fibrosis and extracellular volume for the detection of cardiac allograft vasculopathy.
    van Heeswijk RB; Bastiaansen JAM; Iglesias JF; Degrauwe S; Rotman S; Barras JL; Regamey J; Lauriers N; Tozzi P; Yerly J; Ginami G; Stuber M; Hullin R
    Int J Cardiovasc Imaging; 2020 Mar; 36(3):533-542. PubMed ID: 31724114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optical coherence tomography and intravascular ultrasound evaluation of cardiac allograft vasculopathy with and without intimal neovascularization.
    Ichibori Y; Ohtani T; Nakatani D; Tachibana K; Yamaguchi O; Toda K; Akasaka T; Fukushima N; Sawa Y; Komuro I; Kotani J; Sakata Y
    Eur Heart J Cardiovasc Imaging; 2016 Jan; 17(1):51-8. PubMed ID: 25976347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. European Association of Cardiovascular Imaging/Cardiovascular Imaging Department of the Brazilian Society of Cardiology recommendations for the use of cardiac imaging to assess and follow patients after heart transplantation.
    Badano LP; Miglioranza MH; Edvardsen T; Colafranceschi AS; Muraru D; Bacal F; Nieman K; Zoppellaro G; Marcondes Braga FG; Binder T; Habib G; Lancellotti P;
    Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):919-48. PubMed ID: 26139361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac transplant vasculopathy.
    Aranda JM; Hill J
    Chest; 2000 Dec; 118(6):1792-800. PubMed ID: 11115475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. "Cardiac allograft vasculopathy: Pathogenesis, diagnosis and therapy".
    Pighi M; Gratta A; Marin F; Bellamoli M; Lunardi M; Fezzi S; Zivelonghi C; Pesarini G; Tomai F; Ribichini F
    Transplant Rev (Orlando); 2020 Oct; 34(4):100569. PubMed ID: 32739137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of late-term progression of cardiac allograft vasculopathy in patients with orthotopic heart transplantation using quantitative cardiac
    Shrestha UM; Sciammarella M; Pampaloni MH; Botvinick EH; Gullberg GT; DeMarco T; Seo Y
    Int J Cardiovasc Imaging; 2021 Apr; 37(4):1461-1472. PubMed ID: 33123937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracoronary ultrasound in cardiac transplant recipients. In vivo evidence of "angiographically silent" intimal thickening.
    St Goar FG; Pinto FJ; Alderman EL; Valantine HA; Schroeder JS; Gao SZ; Stinson EB; Popp RL
    Circulation; 1992 Mar; 85(3):979-87. PubMed ID: 1537134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients.
    Javaheri A; Molina M; Zamani P; Rodrigues A; Novak E; Chambers S; Stutman P; Maslanek W; Williams M; Lilly SM; Heeger P; Sayegh MH; Chandraker A; Briscoe DM; Daly KP; Starling R; Ikle D; Christie J; Rame JE; Goldberg LR; Billheimer J; Rader DJ
    J Heart Lung Transplant; 2016 Nov; 35(11):1295-1302. PubMed ID: 27498384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optical coherence tomography for characterization of cardiac allograft vasculopathy after heart transplantation (OCTCAV study).
    Khandhar SJ; Yamamoto H; Teuteberg JJ; Shullo MA; Bezerra HG; Costa MA; Selzer F; Lee JS; Marroquin OC; McNamara DM; Mulukutla SR; Toma C
    J Heart Lung Transplant; 2013 Jun; 32(6):596-602. PubMed ID: 23499356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of optical coherence tomography in pediatric heart transplant patients.
    Ulrich SM; Lehner A; Birnbaum J; Heckel S; Haas NA; Hakami L; Schramm R; Dalla Pozza R; Fischer M; Kozlik-Feldmann R
    Int J Cardiol; 2017 Feb; 228():205-208. PubMed ID: 27866017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive model to assess risk for cardiac allograft vasculopathy: an intravascular ultrasound study.
    Mehra MR; Ventura HO; Chambers R; Collins TJ; Ramee SR; Kates MA; Smart FW; Stapleton DD
    J Am Coll Cardiol; 1995 Nov; 26(6):1537-44. PubMed ID: 7594082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac allograft vasculopathy in Dutch heart transplant recipients.
    Galli G; Caliskan K; Balk AH; van Domburg R; Birim O; Salerno-Uriarte J; Manintveld OC; Constantinescu AA
    Neth Heart J; 2016 Dec; 24(12):748-757. PubMed ID: 27586194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How to Approach the Assessment of Cardiac Allograft Vasculopathy in the Modern Era: Review of Invasive Imaging Modalities.
    Javaheri A; Saha N; Lilly SM
    Curr Heart Fail Rep; 2016 Apr; 13(2):86-91. PubMed ID: 26879390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular endothelial growth factor A is associated with the subsequent development of moderate or severe cardiac allograft vasculopathy in pediatric heart transplant recipients.
    Daly KP; Stack M; Eisenga MF; Keane JF; Zurakowski D; Blume ED; Briscoe DM
    J Heart Lung Transplant; 2017 Apr; 36(4):434-442. PubMed ID: 27865734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac allograft vasculopathy in pediatric heart transplant recipients does early-onset portend a worse prognosis?
    Khoury M; Conway J; Gossett JG; Edens E; Soto S; Cantor R; Koehl D; Barnes A; Exil V; Glass L; Kirklin JK; Zuckerman WA
    J Heart Lung Transplant; 2022 May; 41(5):578-588. PubMed ID: 35172937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors.
    Escobar A; Ventura HO; Stapleton DD; Mehra MR; Ramee SR; Collins TJ; Jain SP; Smart FW; White CJ
    Am J Cardiol; 1994 Nov; 74(10):1042-6. PubMed ID: 7977044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac allograft vasculopathy: advances in diagnosis.
    Cai Q; Rangasetty UC; Barbagelata A; Fujise K; Koerner MM
    Cardiol Rev; 2011; 19(1):30-5. PubMed ID: 21135600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of donor age and donor-recipient age difference on intimal hyperplasia in pediatric patients with young and adult donors vs. adult patients after heart transplantation.
    Ulrich S; Arnold L; Michel S; Tengler A; Rosenthal L; Hausleiter J; Mueller CS; Schnabel B; Stark K; Rizas K; Grabmaier U; Mehilli J; Jakob A; Fischer M; Birnbaum J; Hagl C; Massberg S; Haas N; Pozza RD; Orban M
    Clin Res Cardiol; 2024 Jun; ():. PubMed ID: 38913171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Follow-up study on the utility of von Willebrand factor levels in the diagnosis of cardiac allograft vasculopathy.
    Martínez-Dolz L; Almenar L; Reganon E; Vila V; Chamorro C; Andrés L; Martínez-Sales V; Moro J; Agüero J; Sánchez-Lázaro I; Salvador A
    J Heart Lung Transplant; 2008 Jul; 27(7):760-6. PubMed ID: 18582806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low clinical utility of routine angiographic surveillance in the detection and management of cardiac allograft vasculopathy in transplant recipients.
    Clague JR; Cox ID; Murday AJ; Charokopos N; Madden BP
    Clin Cardiol; 2001 Jun; 24(6):459-62. PubMed ID: 11403507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.